# Pulmonary Disease * **Definition:** A group of progressive lung diseases characterized by airflow limitation and breathing difficulties, often linked to long-term exposure to irritating gases or particulate matter, most commonly from cigarette smoke, requiring ongoing management and treatment. * **Taxonomy:** Specialties / Pulmonary Disease ## News * Selected news on the topic of **Pulmonary Disease**, for healthcare technology leaders * 5K news items are in the system for this topic * Posts have been filtered for tech-related keywords | Date | Title | Source | | --- | --- | --- | | 5/12/2025 | [**Experts Share Winning Strategies for Clinical Care Technology - HealthLeaders Media**](https://www.healthleadersmedia.com/cmo/experts-share-winning-strategies-clinical-care-technology) | [[HealthLeaders Media]] | | 4/8/2025 | [**Chronic Obstructive Pulmonary Disease Market Size Expected to Surge USD 34.76 Bn by 2034**](https://finance.yahoo.com/news/chronic-obstructive-pulmonary-disease-market-150000950.html) | [[Yahoo Finance]] | | 4/7/2025 | [**Attachment styles shape adoption of AI counseling tools, study finds**](https://medicalxpress.com/news/2025-04-styles-ai-tools.html) | [[MedicalXpress]] | | 4/5/2025 | [**Best Doctors for Chronic Obstructive Pulmonary Disease (COPD) in Unicoi, TN**](https://www.usnews.com/doctors/emphysema/tennessee/unicoi) | [[US News and World Report]] | | 4/3/2025 | [**More research needed on health literacy and medication adherence in ethnic minority adults ...**](https://medicalxpress.com/news/2025-04-health-literacy-medication-adherence-ethnic.html) | [[MedicalXpress]] | | 4/3/2025 | [**AutoCOPD-A novel and practical machine learning model for COPD detection using whole ...**](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00098-7/fulltext?rss=yes) | [[The Lancet]] | | 3/17/2025 | [**Wellinks and CareAbout Health Partner to Expand Value-Based COPD Management in New ...**](https://finance.yahoo.com/news/wellinks-careabout-health-partner-expand-150000907.html) | [[Yahoo Finance]] | | 3/10/2025 | [**Mutated DNA Restored to Normal in Gene Therapy Advance - The New York Times**](https://www.nytimes.com/2025/03/10/health/gene-editing-beam-mutation-dna.html) | [[The New York Times]] | | 2/24/2025 | [**Mindfulness practice linked to reduced anxiety and better sleep in COPD patients**](https://medicalxpress.com/news/2025-02-mindfulness-linked-anxiety-copd-patients.html) | [[MedicalXpress]] | | 2/24/2025 | [**Bottling a mouse 'superpower' may heal lungs damaged by premature birth**](https://medicalxpress.com/news/2025-02-bottling-mouse-superpower-lungs-premature.html) | [[MedicalXpress]] | | 2/21/2025 | [**Coreline Soft Leads AI Medical Imaging Innovation at STR 2025 - Morningstar**](https://www.morningstar.com/news/pr-newswire/20250221cn22411/coreline-soft-leads-ai-medical-imaging-innovation-at-str-2025) | [[Morningstar]] | | 2/14/2025 | [**Healthcare Services Market to Grow by USD 6.26 Trillion from 2024 to 2028, Driven by Rising Chronic Disease Prevalence, Report on AI's Impact - Technavio**](https://www.prnewswire.com/news-releases/healthcare-services-market-to-grow-by-usd-6-26-trillion-from-2024-to-2028--driven-by-rising-chronic-disease-prevalence-report-on-ais-impact--technavio-302377048.html) | [[PR Newswire]] | | 2/12/2025 | [**Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025**](https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-26-2025-302374229.html) | [[PR Newswire]] | | 2/12/2025 | [**Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on ...**](https://finance.yahoo.com/news/theravance-biopharma-report-fourth-quarter-110000641.html) | [[Yahoo Finance]] | | 2/6/2025 | [**Using genetics to identify individuals with undiagnosed chronic obstructive pulmonary disease**](https://medicalxpress.com/news/2025-02-genetics-individuals-undiagnosed-chronic-obstructive.html) | [[MedicalXpress]] | | 2/4/2025 | [**AdaptHealth Corp. Announces Fourth Quarter and Full Year 2024 Earnings Release Date ...**](https://finance.yahoo.com/news/adapthealth-corp-announces-fourth-quarter-210500381.html) | [[Yahoo Finance]] | | 2/4/2025 | [**Virtual Pulmonary Rehabilitation with Remote Monitoring for COPD**](https://www.physiciansweekly.com/virtual-pulmonary-rehabilitation-with-remote-monitoring-for-copd/) | [[Physicians Weekly]] | | 2/1/2025 | [**Chronic obstructive pulmonary disease: new therapies and old needs - The Lancet**](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00423-5/fulltext?rss=yes) | [[The Lancet]] | | 1/31/2025 | [**Chronic obstructive pulmonary disease: new therapies and old needs**](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00423-5/fulltext) | [[The Lancet]] | | 1/21/2025 | [**CDC report reveals COPD as the sixth leading cause of death in the U.S.**](https://www.news-medical.net/news/20250121/CDC-report-reveals-COPD-as-the-sixth-leading-cause-of-death-in-the-US.aspx) | [[News Medical Net]] | | 1/20/2025 | [**National Non-Smoking Week: A Call to Breathe Easier by Starting the Quit Journey with Lung Health Foundation**](https://www.globenewswire.com/news-release/2025/01/20/3012277/0/en/National-Non-Smoking-Week-A-Call-to-Breathe-Easier-by-Starting-the-Quit-Journey-with-Lung-Health-Foundation.html) | [[Globe Newswire]] | | 1/17/2025 | [**Next Round of Medicare Drug Price Negotiations to Include Semaglutide**](https://www.ajmc.com/view/next-round-of-medicare-drug-price-negotiations-to-include-semaglutide) | [[AJMC]] | | 1/13/2025 | [**Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market Transformation - Technavio**](https://www.prnewswire.com/news-releases/neuromuscular-disease-therapeutics-market-to-grow-by-usd-13-73-billion-from-2025-2029--driven-by-novel-approvals-and-ai-driven-market-transformation---technavio-302347934.html) | [[PR Newswire]] | | 1/6/2025 | [**Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD**](https://www.news-medical.net/news/20250106/Study-finds-no-clinical-advantage-of-budesonide-inhaler-over-fluticasone-in-COPD.aspx) | [[News Medical Net]] | | 11/27/2024 | [**AI in Healthcare News and Updates**](https://www.healthitanswers.net/ai-in-healthcare-news-and-updates-112724/) | [[Health IT Answers]] | ## Specialty Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **American Lung Association**: A leading organization focused on improving lung health and preventing lung disease through education, advocacy, and research. - **ModuleMD**: A healthcare technology company integrating AI into EHR systems to enhance precision and efficiency in specialty practices, including pulmonology. - **Transpire Bio**: A clinical-stage biopharmaceutical company specializing in inhaled therapeutics for pulmonary diseases. - **Theravance Biopharma**: A biopharmaceutical company focused on developing respiratory medicines, including YUPELRI for COPD. - **Lung Health Foundation**: A leading organization advocating for lung health initiatives and effective use of settlement funds for respiratory health. - **AerWave Medical**: A company developing ultrasound-based lung denervation therapy for COPD and asthma, demonstrating procedural efficiency in clinical studies. - **Vast Therapeutics**: A biotechnology company focused on developing treatments for chronic lung diseases, including cystic fibrosis and infections caused by Pseudomonas aeruginosa. - **AdaptHealth Corp.**: A national leader in providing patient-centered healthcare-at-home solutions, including respiratory health equipment for COPD patients. - **ReAlta Life Sciences**: Focused on developing treatments for acute inflammatory diseases, including COPD, through innovative drug platforms. - **Cipla**: A global pharmaceutical company recognized for its efforts in raising awareness about Chronic Obstructive Pulmonary Disease (COPD) and developing treatments. - **Coreline Soft**: Develops AI-based lung and thoracic imaging solutions, enhancing diagnostics for COPD. - **Insilico Medicine**: A biotechnology company utilizing generative AI for drug development, including treatments for pulmonary diseases. - **Pfizer**: Pharmaceutical company that has developed a bivalent RSV vaccine, relevant for patients with respiratory conditions. - **James P. Kiley, Ph.D.**: Director at the National Heart, Lung, and Blood Institute (NHLBI), involved in research on early detection of respiratory diseases. - **Saban Community Clinic**: A healthcare provider focused on delivering essential medical services to underserved communities, with a strong emphasis on pulmonary care. - **Windward Bio**: A clinical-stage drug development company focused on severe asthma and COPD, with a lead candidate targeting TSLP ligand. - **Higher Life**: An organization that developed the Essential 8 (LE8) scores, which correlate cardiovascular health metrics with COPD risk. - **GSK**: A major pharmaceutical company focused on developing new therapeutic alternatives for respiratory diseases. - **Harbour BioMed**: A biopharmaceutical company developing innovative antibody therapeutics, including treatments for chronic obstructive pulmonary disease (COPD). ### Partnerships and Collaborations - **AstraZeneca and American Lung Association**: Collaborating on the 'Learning to Live with COPD' initiative to educate patients about COPD and improve their quality of life. - **American Lung Association and AstraZeneca**: Partnership to support the 'Learning to Live with COPD' campaign, providing education and resources for COPD patients. - **electronRx and PHA Europe**: Collaboration to develop the purpleDx app for monitoring lung function in chronic respiratory disease patients. - **Harbour BioMed and Sichuan Kelun-Biotech**: Collaborative effort to develop HBM9378/SKB378, a fully human antibody targeting thymic stromal lymphopoietin for COPD treatment. - **Theravance Biopharma and Pfizer/Viatris**: Engaged in licensing agreements for various respiratory programs. - **Cipla's 'Take Charge – I Pledge' campaign**: Engaged 4,350 doctors across six countries to raise awareness about COPD. - **VisionAir Solutions and Lazzaro Medical**: A strategic partnership aimed at advancing treatment options for Tracheobronchomalacia (TBM). - **University Hospitals Health System and Aidoc**: Partnership to enhance detection of critical conditions like pulmonary embolism using AI algorithms. - **Viz.ai and Addario Lung Cancer Medical Institute**: Partnered to enhance early identification and treatment for high-risk patients with lung diseases. - **UC Davis Health and Best Buy's Current Health**: Partnership to enable home monitoring for patients with chronic conditions, including COPD. - **AerWave Medical**: Seeking strategic partnerships to further develop and validate its lung denervation technology. - **Sanofi and Regeneron**: Collaborated to develop Dupixent, which has recently been approved for COPD treatment. - **TidalSense and NHS**: Collaboration to implement the N-Tidal device for COPD diagnosis, focusing on integrating AI technology into healthcare. - **Paratek Pharmaceuticals and Zai Lab Limited**: Collaborate on the development of NUZYRA for treating community-acquired bacterial pneumonia in China. - **Regeneron and Sanofi**: Collaborate on the development and marketing of Dupixent for COPD and other indications. - **Wellinks and Spire Health**: Merged technologies to create a fully integrated Predictive Patient Care company aimed at addressing healthcare challenges posed by COPD. - **FlowMod**: A collaboration between Boston Scientific, Ajax Health, and KKR to develop a minimally invasive catheter-based intervention for heart failure, showcasing the intersection of technology and pulmonary care. - **Wellinks and CareAbout Health**: Strategic partnership to expand access to virtual COPD management programs in New Jersey and Florida. - **Novo Holdings**: Invested $200 million in Windward Bio to support innovative therapies for severe asthma and COPD. - **Children's Medical Center Plano**: Expanded its facilities to improve pediatric specialty care, including advanced imaging and radiology capabilities. ### Innovations, Trends, and Initiatives - **purpleDx**: A cardiopulmonary assessment app that provides real-time data to clinicians for managing chronic respiratory diseases. - **Personalized Medicine**: Emerging trend in COPD treatment focusing on tailored management strategies and innovative therapies. - **Virtual Pulmonary Rehabilitation (V-PR)**: A study showed V-PR as a feasible and effective alternative to center-based rehabilitation for COPD patients. - **Learning to Live with COPD**: A campaign launched by the American Lung Association to educate and support newly diagnosed COPD patients. - **ISM001-055**: A novel drug candidate by Insilico Medicine for treating idiopathic pulmonary fibrosis, showing promising clinical efficacy. - **Syndemic Theory Application**: Proposed approach to address socioeconomic factors and comorbidities in COPD treatment, aiming for value-based collaborative care. - **AI in Pulmonary Disease**: Tulane University developed an AI-based method to detect genetic markers of antibiotic resistance in tuberculosis, potentially improving treatment strategies. - **Preclinical Blood Test**: Developed to identify adults at high risk for severe respiratory conditions by analyzing 32 specific proteins. - **N-Tidal Device**: A handheld AI device for diagnosing COPD by analyzing CO2 patterns in breath, aiming to improve patient experience. - **Positive Airway Pressure Devices Market**: Projected to grow significantly, driven by increasing use in home healthcare settings and rising awareness of respiratory diseases. - **Genetic Testing for COPD**: Research indicating that genetic samples can enhance the identification of undiagnosed COPD cases, potentially leading to earlier interventions. - **Inhaler Therapy Study**: Recent studies comparing inhaler therapies for COPD highlight the need for evidence-based treatment selection to improve patient outcomes. - **Remote Patient Monitoring**: Technologies enhancing patient care for chronic conditions, including COPD, by reducing hospital admissions. - **Wearable Lung Patch**: Developed by Georgia Institute of Technology, this device uses deep learning to detect wheezing, aiding in asthma and COPD diagnosis. - **Tezepelumab Study**: Demonstrated a reduction in COPD exacerbations, highlighting the potential for new treatments in managing the disease. - **Remote Patient Monitoring (RPM)**: An evolving healthcare tool integrating AI-driven analytics and wearable devices for continuous patient care, particularly for chronic conditions like pulmonary diseases. - **AI in COPD Management**: The use of artificial intelligence and digital technologies to enhance diagnosis, treatment, and patient adherence in COPD management. - **High-Intensity Noninvasive Ventilation**: Utilized for treating COPD, demonstrating physiological superiority over traditional low-intensity methods. - **AutoCOPD Model**: A novel multimodal framework for detecting chronic obstructive pulmonary disease (COPD) using quantitative computed tomography (QCT). - **Value-Based Care Programs**: Healthcare providers are implementing tailored solutions to improve medication adherence and chronic disease management, particularly for COPD patients. ### Challenges and Concerns - **Healthcare Access Disparities**: Racial disparities in the diagnosis and treatment of pulmonary diseases, particularly in idiopathic pulmonary fibrosis. - **COPD Management**: Despite effective treatments, many individuals remain undiagnosed, and the disease poses significant risks for respiratory infections and complications. - **Air Pollution Impact**: Research indicates that both indoor and outdoor air pollution significantly exacerbates COPD symptoms, highlighting the need for environmental health considerations in patient care. - **Federal Cuts to Pulmonology Programs**: Recent cuts to CDC personnel dedicated to asthma and respiratory health are expected to negatively impact public health initiatives and increase vulnerability among patients. - **Structural Violence**: COPD is linked to societal factors that lead to diagnostic delays and inadequate care. - **COPD Risk Factors**: The increasing prevalence of COPD, exacerbated by smoking and environmental factors, poses significant public health challenges. - **Medication Management**: COPD patients face increased fall risks due to common medications, necessitating careful management and collaboration between pulmonologists and pharmacists. - **Access to Care**: Concerns regarding equitable healthcare access for COPD patients, emphasizing the need for social justice in treatment and research funding. - **Health Inequities**: COPD disproportionately affects marginalized communities, highlighting the need for healthcare providers to address socioeconomic factors in treatment. - **Economic Burden**: High treatment costs for COPD can create significant financial strain on patients. - **Low Global Diagnosis Rate of COPD**: The need for improved detection methods and the low rate of COPD diagnosis globally. - **Social Isolation and COPD**: Research indicates a significant link between social isolation and increased mortality rates in COPD patients, necessitating targeted interventions. - **Healthcare Costs**: The economic burden of managing chronic respiratory diseases like COPD continues to rise, necessitating innovative solutions to reduce costs. - **Rising Prevalence of COPD**: The diagnosed prevalence of COPD is expected to rise, with a notable gender disparity in cases, necessitating ongoing research and treatment development. - **Air Pollution**: High levels of air pollution continue to pose significant health risks, particularly for individuals with respiratory diseases. - **COPD Treatment Efficacy**: Recent studies indicating that certain inhalers may not improve clinical outcomes for COPD patients, raising questions about treatment protocols. - **Social Isolation**: Research indicates that social isolation significantly raises mortality risk in COPD patients, highlighting the need for targeted interventions. - **COPD Treatment Accessibility**: Despite advancements, there are ongoing concerns about the accessibility and affordability of new COPD treatments. - **Conflicts of Interest**: Concerns regarding potential conflicts of interest in studies related to COPD treatments, highlighting the need for transparency.